logo-loader
HealthPharma & Biotech
Verona Pharma

Verona Pharma's chief medical officer to quit at the end of the month

The search is already underway for Kenneth Newman's replacement

doctor looking at lung x-ray
The company is developing a drug for chronic obstructive pulmonary disease

Respiratory specialist Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said its chief medical officer, Kenneth Newman, is quitting the company at the end of the month to “pursue other opportunities”.

The search is already underway for his replacement.

WATCH: Can Verona Pharma hit the dizzy heights of 5p again?

Chief executive Jan-Anders Karlsson thanked Newman for his “outstanding service” over the past three years.

This included the acceleration into phase IIb clinical trials of Verona’s chronic obstructive pulmonary disease drug candidate.

In total, Newman oversaw seven clinical trials and played an instrumental role in establishing the drug developer’s US presence.

Quick facts: Verona Pharma

Price: £0.46

Market: AIM
Market Cap: £48.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read